Organic Chemicals

Cyclopenthiazide

  • Chemical Name: Cyclopenthiazide
  • CAS: 742-20-1
  • Purity: 99%
Inquiry

Factory Sells Best Quality Cyclopenthiazide 742-20-1 with steady supply

  • Molecular Formula: C13H18ClN3O4S2
  • Molecular Weight: 379.889
  • Appearance/Colour: crystals 
  • Vapor Pressure: 1.29E-14mmHg at 25°C 
  • Melting Point: 238-242ºC 
  • Refractive Index: 1.6 
  • Boiling Point: 605.6 °C at 760 mmHg 
  • PKA: 9.00±0.40(Predicted) 
  • Flash Point: 320.1 °C 
  • PSA: 135.12000 
  • Density: 1.471 g/cm3 
  • LogP: 4.92630 

Cyclopenthiazide(Cas 742-20-1) Usage

World Health Organization (WHO)

Cyclopenthiazide, a thiazide diuretic, was introduced in 1968. It continues to be used mainly in combination drugs.

Drug interactions

Potentially hazardous interactions with other drugs Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect. Anti-arrhythmics: hypokalaemia leads to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised. Antibacterials: avoid administration with lymecycline. Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics. Antiepileptics: increased risk of hyponatraemia with carbamazepine. Antifungals: increased risk of hypokalaemia with amphotericin. Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotension with postsynaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol. Antipsychotics: hypokalaemia increases risk of ventricular arrhythmias with amisulpride; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide - avoid. Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias. Cardiac glycosides: increased toxicity if hypokalaemia occurs. Ciclosporin: increased risk of nephrotoxicity and possibly hypomagnesaemia. Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds. Lithium: excretion reduced, increased toxicity

Metabolism

Cyclopenthiazide appears to be entirely excreted unchanged in the urine.

InChI:InChI=1/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)

742-20-1 Process route

6-chloro-3-cyclopentylmethyl-1,1-dioxo-1,2(4)-dihydro-1λ<sup>6</sup>-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
92017-67-9

6-chloro-3-cyclopentylmethyl-1,1-dioxo-1,2(4)-dihydro-1λ6 -benzo[1,2,4]thiadiazine-7-sulfonic acid amide

cyclopenthiazide
742-20-1,96783-05-0,96783-06-1

cyclopenthiazide

Conditions
Conditions Yield
With sodium tetrahydroborate; aluminium trichloride; In tetrahydrofuran;
chloraminophenamide
121-30-2

chloraminophenamide

2-cyclopentylacetaldehyde
5623-81-4

2-cyclopentylacetaldehyde

cyclopenthiazide
742-20-1,96783-05-0,96783-06-1

cyclopenthiazide

Conditions
Conditions Yield
With hydrogenchloride; In ethanol; for 12h; Ambient temperature;

742-20-1 Upstream products

  • 121-30-2
    121-30-2

    chloraminophenamide

  • 5623-81-4
    5623-81-4

    2-cyclopentylacetaldehyde

  • 92017-67-9
    92017-67-9

    6-chloro-3-cyclopentylmethyl-1,1-dioxo-1,2(4)-dihydro-1λ6 -benzo[1,2,4]thiadiazine-7-sulfonic acid amide

Leave Your Message

*Product Name
CAS
Purity
Quantity
Company name
*Email
*Other Description
*Code
Fields with* are required
Submit